**Areas of Interest**

Research collaborations to early clinical development: The best modality for right target in the right patient at the right time.

<table>
<thead>
<tr>
<th>MEDICAL NEED</th>
<th>BIOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ONCOLOGY</strong></td>
<td>Apoptosis, immuno-oncology (T-cell focus)</td>
</tr>
<tr>
<td>Hematological and solid tumors</td>
<td></td>
</tr>
<tr>
<td><strong>IMMUNO-INFLAMMATION</strong></td>
<td>Cytokine and immune regulation</td>
</tr>
<tr>
<td>Autoimmune disease, including Lupus, Sjögren, systemic sclerosis</td>
<td></td>
</tr>
<tr>
<td><strong>NEUROLOGY</strong></td>
<td>Proteinopathies, neuroinflammation</td>
</tr>
<tr>
<td>Neurodegeneration</td>
<td></td>
</tr>
</tbody>
</table>

[https://servier.com/en/areas-of-expertise/partnering/]
Partnership is embedded in our culture with highly engaged and diverse teams partnering for a shared purpose - contributing to therapeutic progress to serve patient needs. Our partnership approach serves one goal: to bring life-changing treatments to patients faster. We strive to always put patients first, leading to better outcomes for ourselves and our partners.

A partner with strong commitment
Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

A partner with a global presence
With €4.6Bn of revenue in 2018/2019 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

A partner with proven expertise and experience
Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

A partner you can rely on
Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets.

Our areas of interest

**Discovery & Early Clinical Focus**
- **Cancer cell Targeting**
  - Apoptosis (BCL2 family, extrinsic cell death)
  - Novel oncogenes, oncogene stability regulators
  - Epigenetic regulators (with biomarker validation)
  - Synthetic lethality associated with genetic defect

**Immuno-oncology**
- Stroma/ Tumor micro-environment (e.g., genetically-driven immune contexture)
- T cell activation (e.g. intracellular immune checkpoints)
- Immunosuppression (e.g. Treg targeting)
- Innate immunity (e.g. Type I interferon pathway)

**Inflammatory & autoimmune disease**
- Lupus
- Primary Sjögren syndrome
- Systemic sclerosis

**Immuno-inflammatory diseases**
- Synucleinopathies
- Alzheimer’s disease
- ALS
- Huntington’s disease

**Oncology**
- Neurodevelopmental disorders

**Cardiovascular diseases**
- Acquire or license market-ready or mature assets for some geographies